DelveInsight’s, “Primary Sclerosing Cholangitis Pipeline Insight 2023” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Primary Sclerosing Cholangitis pipeline landscape. It covers the Primary Sclerosing Cholangitis pipeline drug profiles, including Primary Sclerosing Cholangitis clinical trials and nonclinical stage products. It also covers the Primary Sclerosing Cholangitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Primary Sclerosing Cholangitis Pipeline Insight Report
Discover the recent breakthroughs happening in the Primary Sclerosing Cholangitis pipeline landscape @ Primary Sclerosing Cholangitis Pipeline Outlook
Recent Developmental Activities in the Primary Sclerosing Cholangitis Treatment Landscape
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts. The condition may lead to cirrhosis of the liver with portal hypertension and end-stage liver disease (ESLD). The main symptoms of primary sclerosing cholangitis (PSC) are feeling tired or weak and having itchy skin. Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen. The cause of PSC is not known. A diagnosis of primary sclerosing cholangitis is made based upon a thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and a variety of specialized tests. Diagnosis is done by cholangiography (magnetic resonance cholangiopancreatography [MRCP] or endoscopic retrograde cholangiopathy [ERCP]). Treatments for primary sclerosing cholangitis focus on managing complications and monitoring liver damage. Endoscopic surgery to remove blockages and enlarge narrowed bile ducts may be of benefit to help prevent liver deterioration in certain cases. Lost vitamins should be replaced when required to prevent complications related to these deficiencies.
Find out more about Primary Sclerosing Cholangitis Medications and Clinical Trials Procedures @ Primary Sclerosing Cholangitis Treatment Landscape
Primary Sclerosing Cholangitis Emerging Drugs
GS-9674: Gilead Sciences
GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.
IMU-838: Immunic
IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn’s Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.
Primary Sclerosing Cholangitis Therapeutic Assessment
There are approx. 14+ key companies which are developing the therapies for Primary Sclerosing Cholangitis. The companies which have their Primary Sclerosing Cholangitis drug candidates in the most advanced stage, i.e. Phase III include, Gilead Sciences.
Learn more about the novel and emerging Primary Sclerosing Cholangitis pipeline therapies @ Primary Sclerosing Cholangitis Ongoing Clinical Trials Analysis
Primary Sclerosing Cholangitis Segmentation
The Primary Sclerosing Cholangitis Pipeline report proffers an integral view of the Primary Sclerosing Cholangitis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.
Scope of the Primary Sclerosing Cholangitis Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Dive deep into rich insights for drugs for Primary Sclerosing Cholangitis, visit @ Primary Sclerosing Cholangitis Key Companies and Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/